Imperial College London
Alternate

DrMartinWalker

Faculty of Medicine, School of Public Health

Honorary Senior Lecturer
 
 
 
//

Contact

 

+44 (0)20 7594 3229m.walker06 CV

 
 
//

Location

 

G2716 South Wharf RoadSt Mary's Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Walker:2020:10.1038/s41467-020-16442-y,
author = {Walker, M and Hamley, JID and Milton, P and Monnot, F and Pedrique, B and Basáñez, M-G},
doi = {10.1038/s41467-020-16442-y},
journal = {Nature Communications},
pages = {1--11},
title = {Designing antifilarial drug trials using clinical trial simulators},
url = {http://dx.doi.org/10.1038/s41467-020-16442-y},
volume = {11},
year = {2020}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Lymphatic filariasis and onchocerciasis are neglected tropical diseases (NTDs) targeted for elimination by mass (antifilarial) drug administration. These drugs are predominantly active against the microfilarial progeny of adult worms. New drugs or combinations are needed to improve patient therapy and to enhance the effectiveness of interventions in persistent hotspots of transmission. Several therapies and regimens are currently in (pre-)clinical testing. Clinical trial simulators (CTSs) project patient outcomes to inform the design of clinical trials but have not been widely applied to NTDs, where their resource-saving payoffs could be highly beneficial. We demonstrate the utility of CTSs using our individual-based onchocerciasis transmission model (EPIONCHO-IBM) that projects trial outcomes of a hypothetical macrofilaricidal drug. We identify key design decisions that influence the power of clinical trials, including participant eligibility criteria and post-treatment follow-up times for measuring infection indicators. We discuss how CTSs help to inform target product profiles.
AU  - Walker,M
AU  - Hamley,JID
AU  - Milton,P
AU  - Monnot,F
AU  - Pedrique,B
AU  - Basáñez,M-G
DO  - 10.1038/s41467-020-16442-y
EP  - 11
PY  - 2020///
SN  - 2041-1723
SP  - 1
TI  - Designing antifilarial drug trials using clinical trial simulators
T2  - Nature Communications
UR  - http://dx.doi.org/10.1038/s41467-020-16442-y
UR  - https://www.nature.com/articles/s41467-020-16442-y
UR  - http://hdl.handle.net/10044/1/79506
VL  - 11
ER  -
Download